Market Overview:
The global anti-neoplastic pharmaceutical agents market is expected to grow at a CAGR of 6.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel and targeted therapies, and growing focus on personalized medicine. Based on type, the global anti-neoplastic pharmaceutical agents market is segmented into hormones and antagonists, microorganism products, plant products, antitumor antibiotics, alkylating agents, antimetabolites, and natural products. Hormones and antagonists held the largest share of the global anti-neoplastic pharmaceutical agents market in 2017 owing to their widespread use in cancer treatment. Antibiotics are also expected to witness high growth during the forecast period due to their ability to target specific types of tumors. Based on application, the global anti-neoplastic pharmaceuticals agent market is segmented into lung cancer bladder cancer breast cancer cervicalcancer leukemia gynecological cancers other cancers). Lung Cancer held the largest share of this market in 2017 owingto its high prevalence across all regions studied herein.
Product Definition:
Anti-neoplastic pharmaceutical agents are those that are used to treat cancer. They work by slowing or stopping the growth of cancer cells.
Hormones and Antagonists:
Hormones and antagonists are used in the treatment of various types of cancer such as prostate, breast, lung, colon/colorectal and other malignant neoplasms. The growth factors that are targeted by these products include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin-like Growth Factor 1 (IGF1) and vascular endothelialgrowth factor (VEGF).
Microorganism Products:
Microorganism Products and it's usage in Anti-Neoplastic Pharmaceutical Agents market is a new term which has been derived to express the use of microorganisms such as bacteria, fungi, viruses or parasites for therapeutic purpose. These products are used in combination with other pharmaceutical agents for treating various types of tumors and cancer. Microorganisms Products have anti-cancerous properties which help in destruction of cell walls of tumor cells leading to death of these cells by different mechanisms.
Application Insights:
The lung cancer segment dominated the global anti-neoplastic pharmaceutical agents market in 2017 and is expected to witness significant growth during the forecast period. Increasing prevalence of smoking and non-smokers exposure to carcinogenic elements such as radon gas, asbestos fibers, and other particulate matter is anticipated to drive the demand for these drugs over the forecast period.
Rising awareness about early diagnosis coupled with increasing availability of diagnostic techniques such as high resolution CT scan is anticipated to boost product penetration in oncology medicines across various applications including lung cancer. In addition, favorable government policies that support access to advanced healthcare services are further likely to propel market growth over the coming years.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing regional market over the forecast period. The presence of a large number of target population and high incidence rate are some of the major factors driving growth in this region. In addition, increasing government initiatives for cancer research and development as well as availability of funds from public & private entities are also contributing towards growth in Asia Pacific region. For instance, Cancer Research UK provides funding for research on several types of cancers including bladder, breast, lung & bronchial cancer among others.
North America held a significant share in global anti-neoplastic pharmaceutical agents market owing to strong R&D base and presence of key players such as Pfizer Inc.; Merck Group; Celgene Corporation; Amgen Inc.; AbbVie Inc.; Biogen Inc., among others (all U.S.).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the anti-neoplastic pharmaceutical agents market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over the next two decades, accounting for nearly 24 million new cases and 17 million deaths each year by 2040. This will create a large demand for anti-neoplastic drugs, which will drive the growth of this market.
- Rising prevalence of lifestyle diseases: The rising prevalence of lifestyle diseases such as obesity and diabetes is also contributing to the growth of the anti-neoplastic pharmaceutical agents market. These diseases are known risk factors for developing various types of cancers such as breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and prostatecancer . Thus, an increasing numberof people are being diagnosed with these cancers every yearand are in need oftreatment withanti- neoplastic drugs .Thiswill further boostthegrowthoftheanti- neoplasticpharmaceuticalagentsmarketin thenear future .
- Technological advancements in anticancer therapies: There has been a significant advancement in anticancer therapies overthe past few years owingto which patients now have a wider range oftreatment options availableto them .This has ledtothe developmentofnewerand more efficaciousanti - ne
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Neoplastic Pharmaceutical Agents Market Research Report
By Type
Hormones and Antagonists, Microorganism Products, Plant Products, Antitumor Antibiotics, Alkylating Agents, Antimetabolites, Natural Products
By Application
Lung Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Leukemia, Gynecological Cancer, Other
By Companies
GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Becton, Dickinson and Company, Pfizer Inc., Novartis AG, AstraZeneca, Gilead
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Neoplastic Pharmaceutical Agents Market Report Segments:
The global Anti-Neoplastic Pharmaceutical Agents market is segmented on the basis of:
Types
Hormones and Antagonists, Microorganism Products, Plant Products, Antitumor Antibiotics, Alkylating Agents, Antimetabolites, Natural Products
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Leukemia, Gynecological Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Becton, Dickinson and Company
- Pfizer Inc.
- Novartis AG
- AstraZeneca
- Gilead
Highlights of The Anti-Neoplastic Pharmaceutical Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hormones and Antagonists
- Microorganism Products
- Plant Products
- Antitumor Antibiotics
- Alkylating Agents
- Antimetabolites
- Natural Products
- By Application:
- Lung Cancer
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Leukemia
- Gynecological Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Neoplastic Pharmaceutical Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-neoplastic pharmaceutical agents are medications used to treat cancer. These drugs can help to slow or stop the growth of cancer cells.
Some of the major players in the anti-neoplastic pharmaceutical agents market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Becton, Dickinson and Company, Pfizer Inc., Novartis AG, AstraZeneca, Gilead.
The anti-neoplastic pharmaceutical agents market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Neoplastic Pharmaceutical Agents Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Neoplastic Pharmaceutical Agents Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Neoplastic Pharmaceutical Agents Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Neoplastic Pharmaceutical Agents Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Neoplastic Pharmaceutical Agents Market Size & Forecast, 2018-2028
4.5.1 Anti-Neoplastic Pharmaceutical Agents Market Size and Y-o-Y Growth
4.5.2 Anti-Neoplastic Pharmaceutical Agents Market Absolute $ Opportunity
Chapter 5 Global Anti-Neoplastic Pharmaceutical Agents Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
5.2.1 Hormones and Antagonists
5.2.2 Microorganism Products
5.2.3 Plant Products
5.2.4 Antitumor Antibiotics
5.2.5 Alkylating Agents
5.2.6 Antimetabolites
5.2.7 Natural Products
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anti-Neoplastic Pharmaceutical Agents Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Bladder Cancer
6.2.3 Breast Cancer
6.2.4 Cervical Cancer
6.2.5 Leukemia
6.2.6 Gynecological Cancer
6.2.7 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Neoplastic Pharmaceutical Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-Neoplastic Pharmaceutical Agents Analysis and Forecast
9.1 Introduction
9.2 North America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
9.6.1 Hormones and Antagonists
9.6.2 Microorganism Products
9.6.3 Plant Products
9.6.4 Antitumor Antibiotics
9.6.5 Alkylating Agents
9.6.6 Antimetabolites
9.6.7 Natural Products
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Bladder Cancer
9.10.3 Breast Cancer
9.10.4 Cervical Cancer
9.10.5 Leukemia
9.10.6 Gynecological Cancer
9.10.7 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anti-Neoplastic Pharmaceutical Agents Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
10.6.1 Hormones and Antagonists
10.6.2 Microorganism Products
10.6.3 Plant Products
10.6.4 Antitumor Antibiotics
10.6.5 Alkylating Agents
10.6.6 Antimetabolites
10.6.7 Natural Products
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Bladder Cancer
10.10.3 Breast Cancer
10.10.4 Cervical Cancer
10.10.5 Leukemia
10.10.6 Gynecological Cancer
10.10.7 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anti-Neoplastic Pharmaceutical Agents Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
11.6.1 Hormones and Antagonists
11.6.2 Microorganism Products
11.6.3 Plant Products
11.6.4 Antitumor Antibiotics
11.6.5 Alkylating Agents
11.6.6 Antimetabolites
11.6.7 Natural Products
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Bladder Cancer
11.10.3 Breast Cancer
11.10.4 Cervical Cancer
11.10.5 Leukemia
11.10.6 Gynecological Cancer
11.10.7 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anti-Neoplastic Pharmaceutical Agents Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
12.6.1 Hormones and Antagonists
12.6.2 Microorganism Products
12.6.3 Plant Products
12.6.4 Antitumor Antibiotics
12.6.5 Alkylating Agents
12.6.6 Antimetabolites
12.6.7 Natural Products
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Bladder Cancer
12.10.3 Breast Cancer
12.10.4 Cervical Cancer
12.10.5 Leukemia
12.10.6 Gynecological Cancer
12.10.7 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anti-Neoplastic Pharmaceutical Agents Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Type
13.6.1 Hormones and Antagonists
13.6.2 Microorganism Products
13.6.3 Plant Products
13.6.4 Antitumor Antibiotics
13.6.5 Alkylating Agents
13.6.6 Antimetabolites
13.6.7 Natural Products
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anti-Neoplastic Pharmaceutical Agents Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Bladder Cancer
13.10.3 Breast Cancer
13.10.4 Cervical Cancer
13.10.5 Leukemia
13.10.6 Gynecological Cancer
13.10.7 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Neoplastic Pharmaceutical Agents Market: Competitive Dashboard
14.2 Global Anti-Neoplastic Pharmaceutical Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline plc.
14.3.2 F. Hoffmann-La Roche Ltd
14.3.3 Eli Lilly and Company
14.3.4 Bristol-Myers Squibb Company
14.3.5 Becton, Dickinson and Company
14.3.6 Pfizer Inc.
14.3.7 Novartis AG
14.3.8 AstraZeneca
14.3.9 Gilead
